At present time, selective estrogen receptor downregulators (SERDs) that act as pure antagonists by interfering with the binding of estradiol to estrogen receptors (ERs) are used for hormone receptor-positive (HR+) breast cancer treatment [32]. This evidence concerns the gene NR4A1 and breast cancer.